Gilead Sciences (GILD) Misses Q4 EPS by 83c; Offers 2022 Guidance
Get Alerts GILD Hot Sheet
Price: $146.85 +1.82%
EPS Growth %: -14.2%
Financial Fact:
Product sales: 7.41B
Today's EPS Names:
AEHR, VFS, CMTL, More
EPS Growth %: -14.2%
Financial Fact:
Product sales: 7.41B
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $0.69, $0.83 worse than the analyst estimate of $1.52. Revenue for the quarter came in at $7.2 billion versus the consensus estimate of $6.51 billion.
GUIDANCE:
Gilead Sciences sees FY2022 EPS of $6.20-$6.70, versus the consensus of $6.91. Gilead Sciences sees FY2022 revenue of $23.8-24.3 billion, versus the consensus of $24.39 billion.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Levi (LEVI) Tops Q3 EPS by 12c; raises guidance
- Constellation Brands (STZ) Beats Q2 EPS by 13c, Revenue Beats, Offers Guidance
- Gilead Sciences (GILD) PT Raised to $170 at JPMorgan
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share